real-time news and commentary for investors
Monday, May 6
Appearing a bit late to the party, Jefferies raises its price target on Regeneron...
Appearing a bit late to the party, Jefferies raises its price target on Regeneron Pharmaceuticals (REGN -1.3%) to $247 from $179 citing the company's top line, EYLEA sales-driven earnings beat. Jefferies is responding to REGN's hike of FY13 EYLEA sales estimates — the company pointed to a strong ex-U.S. rollout. Q1 sales of the macular degeneration injection were $314M compared to $124M in Q1 2012.